CDK4/6 inhibitors consistently enhance PFS and OS in HR+/HER2- advanced breast cancer patients, regardless of treatment line, endocrine therapy type, ESR1 and TP53 status, follow-up duration, age, ethnicity, ECOG performance status, previous chemotherapy or endocrine therapy, and metastatic status. Here, ESR1 is linked to breast carcinoma.